# The Norwegian Tenecteplase Stroke Trial 2

> **NCT03854500** · PHASE3 · TERMINATED · sponsor: **Haukeland University Hospital** · enrollment: 201 (actual)

## Conditions studied

- Stroke, Acute
- Cerebrovascular Disorders
- Ischemic Stroke

## Interventions

- **DRUG:** Tenecteplase
- **DRUG:** Alteplase

## Key facts

- **NCT ID:** NCT03854500
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-28
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 201 (ACTUAL)
- **Why stopped:** Per protocol safety analysis 200 patients showed a significant difference in bleeding rates between the two drug groups.
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03854500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03854500, "The Norwegian Tenecteplase Stroke Trial 2". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT03854500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*